GM1 specifically interacts with α-synuclein and inhibits fibrillation

Biochemistry

Volumn 46, Issue 7, 2007, Pages 1868-1877

  Martinez, Zak ^a   Zhu, Min ^a   Han, Shubo ^a   Fink, Anthony L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; BIOLOGICAL MEMBRANES; BRAIN; DISEASE CONTROL; LIPIDS; OLIGOMERS;

BRAIN GANGLIOSIDES; PRESYNAPTIC REGION; SMALL UNILAMELLAR VESICLES (SUV); SPHINGOLIPIDS;

PROTEINS;

ALPHA SYNUCLEIN; GANGLIOSIDE GM1; GANGLIOSIDE GM2; GANGLIOSIDE GM3; GANGLIOTETRAOSYLCERAMIDE; MUTANT PROTEIN;

ALPHA HELIX; ARTICLE; CAVEOLA; LIPID RAFT; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRESYNAPTIC MEMBRANE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN LIPID INTERACTION; PROTEIN LOCALIZATION;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ALPHA-SYNUCLEIN; CARBOHYDRATE SEQUENCE; G(M1) GANGLIOSIDE; G(M2) GANGLIOSIDE; G(M3) GANGLIOSIDE; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERS; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; SPHINGOLIPIDS;

EID: 33847022701     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi061749a     Document Type: Article

References (85)

1. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Di Iorio, G., Golbe, L. I., and Nussbaum, R. L. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease, Science 276, 2045-2047.
2. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J. T., Schols, L., and Riess, O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease, Nat. Genet. 18, 106-108.
3. Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., Lincoln, S., Crawley, A., Hanson, M., Maraganore, D., Adler, C., Cookson, M. R., Muenter, M., Baptista, M., Miller, D., Blancato, J., Hardy, J., and Gwinn-Hardy, K. (2003) alpha-Synuclein locus triplication causes Parkinson's disease, Science 302, 841.
4. Segrest, J. P., De Loof, H., Dohlman, J. G., Brouillette, C. G., and Anantharamaiah, G. M. (1990) Amphipathic helix motif: classes and properties, Proteins 8, 103-117.
5. Segrest, J. P., Jones, M. K., De Loof, H., Brouillette, C. G., Venkatachalapathi, Y. V., and Anantharamaiah, G. M. (1992) The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function, J. Lipid Res. 33, 141-166.
6. Maroteaux, L., Campanelli, J. T., and Scheller, R. H. (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal, J. Neurosci. 8, 2804-2815.
7. Davidson, W. S., Jonas, A., Clayton, D. F., and George, J. M. (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes, J. Biol. Chem. 273, 9443-9449.
8. Epand, R. M. (1993) The Amphipathic Helix, CRC Press, Boca Raton, FL.
9. Jensen, P. H., Nielsen, M. S., Jakes, R., Dotti, C. G., and Goedert, M. (1998) Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation, J. Biol. Chem. 273, 26292-26294.
10. Jenco, J. M., Rawlingson, A., Daniels, B., and Morris, A. J. (1998) Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins, Biochemistry 37, 4901-4909.
11. Clayton, D. F. and George, J. M. (1999) Synucleins in synaptic plasticity and neurodegenerative disorders, J. Neurosci. Res. 58, 120-129.
12. Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., de Silva, H. A., Kittel, A., and Saitoh, T. (1995) The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system, Neuron 14, 467-475.
13. Irizarry, M. C., Kim, T. W., McNamara, M., Tanzi, R. E., George, J. M., Clayton, D. F., and Hyman, B. T. (1996) Characterization of the precursor protein of the non-A beta component of senile plaques (NACP) in the human central nervous system, J. Neuropathol. Exp. Neurol. 55, 889-895.
14. Withers, G. S., George, J. M., Banker, G. A., and Clayton, D. F. (1997) Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons, Brain Res. Dev. Brain Res. 99, 87-94.
15. Murphy, D. D., Rueter, S. M., Trojanowski, J. Q., and Lee, V. M. (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons, J. Neurosci. 20, 3214-3220.
16. Ostrerova, N., Petrucelli, L., Farrer, M., Mehta, N., Choi, P., Hardy, J., and Wolozin, B. (1999) alpha-Synuclein shares physical and functional homology with 14-3-3 proteins, J. Neurosci. 19, 5782-5791.
17. Iwata, A., Miura, S., Kanazawa, I., Sawada, M., and Nukina, N. (2001) alpha-Synuclein forms a complex with transcription factor Elk-1, J. Neurochem. 77, 239-252.
18. Ahn, B. H., Rhim, H., Kim, S. Y., Sung, Y. M., Lee, M. Y., Choi, J. Y., Wolozin, B., Chang, J. S., Lee, Y. H., Kwon, T. K., Chung, K. C., Yoon, S. H., Hahn, S. J., Kim, M. S., Jo, Y. H., and Min, D. S. (2002) Alpha-synuclein interacts with phospholipase D isozymes and inhibits pervanadate induced phospholipase D activation in human embryonic kidney 293 cells, J. Biol. Chem.
19. Hashimoto, M., Takenouchi, T., Rockenstein, E., and Masliah, E. (2003) alpha-Synuclein up-regulates expression of caveolin-1 and down-regulates extracellular signal-regulated kinase activity in B103 neuroblastoma cells: role in the pathogenesis of Parkinson's disease, J. Neurochem. 85, 1468-1479.
20. Impey, S., Obrietan, K., and Storm, D. R. (1999) Making new connections: role of ERK/MAP kinase signaling in neuronal plasticity, Neuron 23, 11-14.
21. Cox, M. E., and Parsons, S. J. (1997) Roles for protein kinase C and mitogen-activated protein kinase in nicotine-induced secretion from bovine adrenal chromaffin cells, J. Neurochem. 69, 1119-1130.
22. Bloch-Shilderman, E., Jiang, H., Abu-Raya, S., Linial, M., and Lazarovici, P. (2001) Involvement of extracellular signal-regulated kinase (ERK) in pardaxin-induced dopamine release from PC12 cells, J. Pharmacol. Exp. Ther. 296, 704-711.
23. Lisanti, M. P., Scherer, P. E., Tang, Z., and Sargiacomo, M. (1994) Caveolae, caveolin and caveolin-rich membrane domains: a signalling hypothesis, Trends Cell Biol. 4, 231-235.
24. Parton, R. G. and Simons, K. (1995) Digging into caveolae, Science 269, 1398-1399.
25. Harder, T. and Simons, K. (1997) Caveolae, DIGs, and the dynamics of sphingolipid-cholesterol microdomains, Curr. Opin. Cell Biol. 9, 534-542.
26. Brown, D. A., and London, E. (1998) Functions of lipid rafts in biological membranes, Annu. Rev. Cell Dev. Biol. 14, 111-136.
27. Pike, L. J., Han, X., Chung, K. N., and Gross, R. W. (2002) Lipid rafts are enriched in arachidonic acid and plasmenylethanolamine and their composition is independent of caveolin-1 expression: a quantitative electrospray ionization/mass spectrometric analysis, Biochemistry 41, 2075-2088.
28. Betts, S. D., and King, J. (1998) Cold rescue of the thermolabile tailspike intermediate at the junction between productive folding and off-pathway aggregation, Protein Sci. 7, 1516-1523.
29. Galbiati, F., Razani, B., and Lisanti, M. P. (2001) Emerging themes in lipid rafts and caveolae, Cell 106, 403-411.
30. Razani, B., Woodman, S. E., and Lisanti, M. P. (2002) Caveolae: from cell biology to animal physiology, Pharmacol. Rev. 54, 431-467.
31. Rothberg, K. G., Heuser, J. E., Donzell, W. C., Ying, Y. S., Glenney, J. R., and Anderson, R. G. (1992) Caveolin, a protein component of caveolae membrane coats, Cell 68, 673-682.
32. Parton, R. G. (1994) Ultrastructural localization of gangliosides; GM1 is concentrated in caveolae, J. Histochem. Cytochem. 42, 155-166.
33. Masserini, M., Palestinii, P., and Pitto, M. (1999) Glycolipid-enriched caveolae and caveolae-like domains in the nervous system, J. Neurochem. 73, 1-11.
34. Sharom, F. J., and Grant, C. W. (1978) A model for ganglioside behaviour in cell membranes, Biochim. Biophys. Acta 507, 280-293.
35. Thompson, T. E., and Tillack, T. W. (1985) Organization of glycosphingolipids in bilayers and plasma membranes of mammalian cells, Annu. Rev. Biophys. Biophys. Chem. 14, 361-386.
36. Fortin, D. L., Troyer, M. D., Nakamura, K., Kubo, S., Anthony, M. D., and Edwards, R. H. (2004) Lipid rafts mediate the synaptic localization of alpha-synuclein, J. Neurosci. 24, 6715-6723.
37. Conway, K. A., Harper, J. D., and Lansbury, P. T. (1998) Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease, Nat. Med. 4, 1318-1320.
38. Zhu, M. and Fink, A. L. (2003) Lipid binding inhibits alpha-synuclein fibril formation, J. Biol. Chem. 278, 16873-16877.
39. Zhu, M., Han, S., Zhou, F., Carter, S. A., and Fink, A. L. (2004) Annular oligomeric amyloid intermediates observed by in situ atomic force microscopy, J. Biol. Chem. 279, 24452-24459.
40. Hokenson, M. J., Uversky, V. N., Goers, J., Yamin, G., Munishkina, L. A., and Fink, A. L. (2004) Role of individual methionines in the fibrillation of methionine-oxidized alpha-synuclein, Biochemistry 43, 4621-4633.
41. Edidin, M. (2003) The state of lipid rafts: from model membranes to cells, Annu. Rev. Biophys. Biomol. Struct. 32, 257-283.
42. Gazzotti, J., Sonnino, S., and Ghidoni, R. (1985) Normal-phase HPLC separation of non-derivatized ganglioside mixtures, J. Chromatogr. 348, 371-378.
43. Naiki, H., Higuchi, K., Hosokawa, M., and Takeda, T. (1989) Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T, Anal. Biochem. 177, 244-249.
44. LeVine, H. (1993) Thioflavine-T interaction with synthetic Alzheimers disease β-amyloid peptides-Detection of amyloid aggregation in solution, Protein Sci. 2, 404-410.
45. Uversky, V. N., Lee, H. J., Li, J., Fink, A. L., and Lee, S. J. (2001) Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations, J. Biol. Chem. 276, 43495-43498.
46. Uversky, V. N., Li, J., Souillac, P. O., Millett, I. S., Doniach, S., Jakes, R., Goedert, M., and Fink, A. L. (2002) Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins, J. Biol. Chem. 277, 11970-11978.
47. Jo, E., McLaurin, J., Yip, C. M., George-Hyslop, P., and Fraser, P. E. (2000) alpha-Synuclein membrane interactions and lipid specificity, J. Biol. Chem. 275, 34328-34334.
48. Conway, K. A., Lee, S. J., Rochet, J. C., Ding, T. T., Williamson, R. E., and Lansbury, P. T., Jr. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy, Proc. Natl. Acad. Sci. U.S.A. 97, 571-576.
49. Perrin, R. J., Woods, W. S., Clayton, D. F., and George, J. M. (2000) Interaction of human alpha-synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis, J. Biol. Chem. 275, 34393-34398.
50. Chandra, S., Chen, X., Rizo, J., Jahn, R., and Sudhof, T. C. (2003) A broken alpha-helix in folded alpha-synuclein, J. Biol. Chem.
51. Bussell, R., Jr., and Eliezer, D. (2003) A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins, J. Mol. Biol. 329, 763-778.
52. Ramakrishnan, M., Jensen, P. H., and Marsh, D. (2003) Alpha-synuclein association with phosphatidylglycerol probed by lipid spin labels, Biochemistry 42, 12919-12926.
53. Bussell, R., Jr., Ramlall, T. F., and Eliezer, D. (2005) Helix periodicity, topology, and dynamics of membrane-associated {alpha}-synuclein, Protein Sci.
54. Schneider, J. S., Roeltgen, D. P., Mancall, E. L., Chapas-Crilly, J., Rothblat, D. S., and Tatarian, G. T. (1998) Parkinson's disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study, Neurology 50, 1630-1636.
55. Pope-Coleman, A., and Schneider, J. S. (1998) Effects of chronic GM1 ganglioside treatment on cognitive and motor deficits in a slowly progressing model of Parkinsonism in non-human primates, Restor. Neurol. Neurosci. 12, 255-266.
56. Sautter, J., Hoglinger, G. U., Oertel, W. H., and Earl, C. D. (2000) Systemic treatment with GM1 ganglioside improves survival and function of cryopreserved embryonic midbrain grafted to the 6-hydroxydopamine-lesioned rat striatum, Exp. Neurol. 164, 121-129.
57. Pope-Coleman, A., Tinker, J. P., and Schneider, J. S. (2000) Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys, Synapse 36, 120-128.
58. Schneider, J. S., and Rothblat, D. S. (2000) Differences in release and clearance of extracellular dopamine in the striatum after spontaneous or GM1-ganglioside-stimulated recovery from experimental Parkinsonism, Restor. Neurol. Neurosci. 16, 97-104.
59. Zappia, M., Crescibene, L., Bosco, D., Arabia, G., Nicoletti, G., Bagala, A., Bastone, L., Napoli, I. D., Caracciolo, M., Bonavita, S., Di Costanzo, A., Gambardella, A., and Quattrone, A. (2002) Anti-GM1 ganglioside antibodies in Parkinson's disease, Acta Neurol. Scand. 106, 54-57.
60. Roze, E., Paschke, E., Lopez, N., Eck, T., Yoshida, K., Maurel-Ollivier, A., Doummar, D., Caillaud, C., Galanaud, D., Billette, D., V., Vidailhet, M., and Roubergue, A. (2005) Dystonia and parkinsonism in GM1 type 3 gangliosidosis, Mov. Disord.
61. Toffano, G., Savoini, G., Moroni, F., Lombardi, G., Calza, L., and Agnati, L. F. (1983) GM1 ganglioside stimulates the regeneration of dopaminergic neurons in the central nervous system, Brain Res. 261, 163-166.
62. Schneider, J. S., Kean, A., and DiStefano, L. (1995) GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice, J. Neurosci. Res. 42, 117-123.
63. Varkonyi, J., Rosenbaum, H., Baumann, N., MacKenzie, J. J., Simon, Z., Aharon-Peretz, J., Walker, J. M., Tayebi, N., and Sidransky, E. (2003) Gaucher disease associated with parkinsonism: Four further case reports, Am. J. Med. Genet. 116A, 348-351.
64. Wong, K., Sidransky, E., Verma, A., Mixon, T., Sandberg, G. D., Wakefield, L. K., Morrison, A., Lwin, A., Colegial, C., Allman, J. M., and Schiffmann, R. (2004) Neuropathology provides clues to the pathophysiology of Gaucher disease, Mol. Genet. Metab. 82, 192-207.
65. Goker-Alpan, O., Schiffmann, R., LaMarca, M. E., Nussbaum, R. L., Inerney-Leo, A., and Sidransky, E. (2004) Parkinsonism among Gaucher disease carriers, J. Med. Genet. 41, 937-940.
66. Lwin, A., Orvisky, E., Goker-Alpan, O., LaMarca, M. E., and Sidransky, E. (2004) Glucocerebrosidase mutations in subjects with parkinsonism, Mol. Genet. Metab. 81, 70-73.
67. Sidransky, E. (2005) Gaucher disease and parkinsonism, Mol. Genet. Metab. 84, 302-304.
68. Zimran, A., Neudorfer, O., and Elstein, D. (2005) The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews, N. Engl. J. Med. 352, 728-731.
69. Suzuki, K., Iseki, E., Katsuse, O., Yamaguchi, A., Katsuyama, K., Aoki, I., Yamanaka, S., and Kosaka, K. (2003) Neuronal accumulation of alpha- and beta-synucleins in the brain of a GM2 gangliosidosis mouse model, Neuroreport 14, 551-554.
70. Schlossmacher, M. G., Cullen, V., and Muthing, J. (2005) The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews, N. Engl. J. Med. 352, 728-731.
71. Kubo, S. I., Nemani, V. M., Chalkley, R. J., Anthony, M. D., Hattori, N., Mizuno, Y., Edwards, R. H., and Fortin, D. L. (2005) A combinatorial code for the interaction of alpha -synuclein with membranes, J. Biol. Chem.
72. Olive, S., Dubois, C., Schachner, M., and Rougon, G. (1995) The F3 neuronal glycosylphosphatidylinositol-linked molecule is localized to glycolipid-enriched membrane subdomains and interacts with L1 and fyn kinase in cerebellum, J. Neurochem. 65, 2307-2317.
73. Vey, M., Pilkuhn, S., Wille, H., Nixon, R., DeArmond, S. J., Smart, E. J., Anderson, R. G., Taraboulos, A., and Prusiner, S. B. (1996) Subcellular colocalization of the cellular and scrapie prion proteins in caveolae-like membranous domains, Proc. Natl. Acad. Sci. U.S.A. 93, 14945-14949.
74. Wu, C., Butz, S., Ying, Y., and Anderson, R. G. (1997) Tyrosine kinase receptors concentrated in caveolae-like domains from neuronal plasma membrane, J. Biol. Chem. 272, 3554-3559.
75. Kubo, S. I., Nemani, V. M., Chalkley, R. J., Anthony, M. D., Hattori, N., Mizuno, Y., Edwards, R. H., and Fortin, D. L. (2005) A combinatorial code for the interaction of alpha-synuclein with membranes, J. Biol. Chem.
76. Jo, E., Fuller, N., Rand, R. P., George-Hyslop, P., and Fraser, P. E. (2002) Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein, J. Mol. Biol. 315, 799-807.
77. Wiegandt H. (1985) Glycolipids, pp 199-260, Elsevier, Amsterdam.
78. Yu, R. K., and Saito, M. (1989) Book Title (Margolis, R. U., and Margolis, R. K., Eds.) pp 1-41, Plenum, New York.
79. Tettamanti, G., and Riboni, L. (1993) Gangliosides and modulation of the function of neural cells, Adv. Lipid Res. 25, 235-267.
80. Hansson, H. A., Holmgren, J., and Svennerholm, L. (1977) Ultrastructural localization of cell membrane GM1 ganglioside by cholera toxin, Proc. Natl. Acad. Sci. U.S.A. 74, 3782-3786.
81. Choo-Smith, L. P., Garzon-Rodriguez, W., Glabe, C. G., and Surewicz, W. K. (1997) Acceleration of amyloid fibril formation by specific binding of abeta-(1-40) peptide to ganglioside-containing membrane vesicles, J. Biol. Chem. 272, 22987-22990.
82. Kakio, A., Nishimoto, S., Yanagisawa, K., Kozutsumi, Y., and Matsuzaki, K. (2002) Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid, Biochemistry 41, 7385-7390.
83. Kakio, A., Nishimoto, S. I., Yanagisawa, K., Kozutsumi, Y., and Matsuzaki, K. (2001) Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid, J. Biol. Chem. 276, 24985-24990.
84. McLaurin, J., Franklin, T., Fraser, P. E., and Chakrabartty, A. (1998) Structural transitions associated with the interaction of Alzheimer beta-amyloid peptides with gangliosides, J. Biol. Chem. 273, 4506-4515.
85. McLaurin, J., and Chakrabartty, A. (1996) Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity, J. Biol. Chem. 271, 26482-26489.